About us
NovalGen’s first pipeline product is a proprietary first in class bispecific T cell engager therapies that can safely harness the immune system to fight a wide range of cancers.
Clinical-stage company developing breakthrough multi-specific biologics to enhance patient outcomes across autoimmune, oncological, and other immunological disorders
Explore
Developing a first-in-class autoregulation technology to create safer drugs
Our strategy
Our technologies
We are changing the paradigm of cancer therapy with our immunotherapy technology. Our focus is on the next generation of bispecific antibody technology to generate transformative outcomes in patients.
Pipeline
To create and capture the value of our pipeline we have built a strong, vibrant network between academia and various strategic partners, enabling us to leverage their strengths and capabilities, alongside our own, to progress our pipeline safely and expediently through the clinic.